Rivaroxaban

Lus piav qhia luv luv:

API lub npe Qhov taw qhia Specification US DMF EU DMF CEP
Rivaroxaban Anticoagulant Hauv tsev TDP    


Product Detail

Khoom cim npe

KHOOM PLIG

Keeb kwm

Rivaroxaban, 5-chloro-N-[[(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl]methyl]thiophene-2 -carboxamide, yog ib qho muaj zog me me-molecule inhibitor ntawm Xa uas yog ib qho kev coagulation ntawm ib qho tseem ceeb juncture nyob rau hauv cov ntshav coagulation txoj kev uas ua rau cov tiam ntawm thrombin thiab tsim cov hlab ntsha.Rivaroxaban khi rau Tyr288 hauv S1 hnab tshos ntawm yam Xa los ntawm kev sib cuam tshuam ntawm Tyr288 thiab cov tshuaj chlorine hloov ntawm chlorothiophene moiety.Cov inhibition yog thim rov qab (koff = 5x10-3s-1), ceev (kon = 1.7x107 mol / L-1 s-1), thiab nyob rau hauv ib qho concentration-dependent yam (Ki = 0.4 nmol / L).Rivaroxaban tam sim no tab tom kawm txog kev kho mob ntawm VTE, kev tiv thaiv kab mob plawv hauv cov neeg mob uas mob hlab ntsha tawg, tiv thaiv mob stroke hauv cov neeg mob atrial fibrillation.

Kev siv

Elisabeth Perzborn, Susanne Roehrig, Alexander Straub, Dagmar Kubitza, Wolfgang Mueck, thiab Volker Laux.Rivaroxaban: qhov ncauj tshiab Xa inhibitor.Arterioscler Thromb Vasc Biol 2010;30(3): 376-381

Kev piav qhia

Rivaroxaban (BAY 59-7939) yog ib qho muaj zog heev,xaiv thiab ncaj qha Factor Xa (FXa) inhibitor, ua tiav qhov muaj zog hauv kev tiv thaiv FXa potency (IC50 0.7 nM; Ki 0.4 nM).

 

Hauv Vitro

Rivaroxaban (BAY 59-7939) yog qhov ncauj, ncaj qha Factor Xa (FXa) inhibitor hauv kev txhim kho rau kev tiv thaiv thiab kho cov hlab ntsha thiab venous thrombosis.Rivaroxaban sib tw inhibits tib neeg FXa (Ki 0.4 nM) nrog> 10 000-fold ntau dua selectivity dua rau lwm cov serine proteases;Nws kuj inhibits kev ua haujlwm prothrombinase (IC50 2.1 nM).Rivaroxaban inhibits endogenous FXa ntau zog nyob rau hauv tib neeg thiab luav plasma (IC50 21 nM) dua nas plasma (IC50 290 nM).Nws ua kom pom cov nyhuv anticoagulant hauv tib neeg plasma, ob npaug ntawm lub sijhawm prothrombin (PT) thiab ua kom lub sijhawm thromboplastin ib nrab ntawm 0.23 thiab 0.69.μM, raws.

 

Rivaroxaban (BAY 59-7939) yog lub zog thiab xaiv, ncaj qha FXa inhibitor nrog zoo heev hauv vivo kev ua si thiab qhov ncauj zoo bioavailability.Rivaroxaban (BAY 59-7939), tswj los ntawm iv bolus ua ntej thrombus induction, txo cov thrombus tsim (ED50 0.1 mg / kg), inhibits FXa, thiab prolongs PT koob tshuaj nyob ntawm seb.PT thiab FXa cuam tshuam me ntsis ntawm ED50 (1.8-fold nce thiab 32% inhibition, feem).Ntawm 0.3 mg / kg ( koob tshuaj ua rau yuav luag tag nrho inhibition ntawm thrombus tsim), Rivaroxaban me ntsis prolongs PT (3.2).±0.5-fold) thiab inhibits FXa kev ua haujlwm (65±3%).

 

Cia

Hmoov

-20 ° C

3 xyoo
 

4 ° C

2 xyoo
Hauv cov kuab tshuaj

-80 ° C

6 hli
 

-20 ° C

1 hli

Cov qauv tshuaj

Rivaroxaban

CERTIFICATE

2018 GMP-2
原料药GMP证书201811(captopril ,thalidomide etc)
GMP-of-PMDA-in-Chanyoo-平成28年08月03日 Nantong-Chanyoo-Pharmatech-Co
FDA-EIR-Letter-201901

QUALITY MANAGEMENT

Quality management1

Tswv yim18Quality Consistency Evaluation tej yaam num uas tau pom zoo4, thiab6tej yaam num raug tso cai.

Quality management2

Advanced thoob ntiaj teb kev tswj hwm qhov system tau tso lub hauv paus ruaj khov rau kev muag khoom.

Quality management3

Kev saib xyuas zoo ua haujlwm los ntawm tag nrho lub neej voj voog ntawm cov khoom kom ntseeg tau tias qhov zoo thiab kho cov nyhuv.

Quality management4

Pab Pawg Kev Tswj Xyuas Kev Tswj Xyuas Kev Ua Haujlwm txhawb nqa qhov kev xav tau zoo thaum lub sijhawm thov thiab tso npe.

PRODUCTION MANAGEMENT

cpf5
cpf6

Kauslim Countec Lub raj mis ntim kab

cpf7
cpf8

Taiwan CVC Lub raj mis ntim kab

cpf9
cpf10

Ltalis CAM Board Ntim Kab

cpf11

German Fette Compacting Tshuab

cpf12

Nyiv Viswill Tablet Detector

cpf14-1

DCS Control Room

PARTNER

Kev koom tes thoob ntiaj teb
International cooperation
Kev koom tes hauv tsev
Domestic cooperation

  • Yav dhau los:
  • Tom ntej:

  • Sau koj cov lus ntawm no thiab xa tuaj rau peb

    Cov khoom qeb